TriSalus Life Sciences, Inc. Retained Earnings
TriSalus Life Sciences, Inc. (TLSI) had Retained Earnings of -$338.23 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-06
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$338.23M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$329.04M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$330.58M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$320.97M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$338.23M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | -$329.04M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | -$330.58M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | -$320.97M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | -$298.21M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | -$289.92M 10-Q · filed 2025-05-15 | |
| 2024-12-31 | -$279.55M 10-K · filed 2026-03-05 | |
| 2024-09-30 | -$269.44M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | -$265.93M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | -$261.60M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | -$249.50M 10-K/A · filed 2025-05-30 | -$248.38M 10-K · filed 2024-04-11 |
| 2023-09-30 | -$212.87M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | -$15.12M 10-Q · filed 2023-08-02 | |
| 2023-03-31 | -$13.86M 10-Q · filed 2023-05-12 | |
| 2022-12-31 | -$186.36M 10-K · filed 2024-04-11 | -$13.27M 10-K · filed 2023-03-22 |
| 2022-09-30 | -$11.66M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | -$11.54M 10-Q · filed 2022-08-10 | |
| 2022-03-31 | -$13.88M 10-Q · filed 2022-05-11 | |
| 2021-12-31 | -$16.72M 10-K · filed 2023-03-22 | |
| 2021-09-30 | -$19.61M 10-Q/A · filed 2021-12-13 | |
| 2021-06-30 | -$21.48M 10-Q/A · filed 2021-12-13 | -$704.56K 10-Q · filed 2021-08-16 |
| 2021-03-31 | -$21.86M 10-Q/A · filed 2021-12-13 | -$1.08M 10-Q · filed 2021-06-28 |
| 2020-12-31 | -$21.49M 10-K · filed 2022-03-03 | -$711.39K 10-Q · filed 2021-06-28 |
| 2020-12-22 | -$21.30M 10-K/A · filed 2021-12-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |